Newsletter | January 13, 2021

01.13.21 -- Going Public In Mid-Pandemic
 
Sponsor
Featured Articles
Going Public In Mid-Pandemic
 

Just as the COVID-19 pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.
China’s Proposed IP Law Changes May Drive Pharma Innovation
 

While many pharma companies with a global footprint currently conduct R&D in China, their R&D investment is relatively small when compared to their U.S. R&D spending. That paradigm may change soon, as China is taking steps to create an innovation-based pharmaceutical industry that favors investment in R&D. 
Transforming Your Organizational Mindset On Quality Compliance
 

How can you embed quality compliance in company culture without sacrificing business objectives? A life sciences workforce will embrace quality compliance only if they consistently observe leaders modeling the way. Judging from five-year trends on FDA Form 483s and warning letters, this has proven elusive.
E-Books
Companies To Watch: 2020
 

In 2020 we profiled 11 biopharma companies in our “Companies To Watch” section. These companies focused on a range of therapeutics including antifungals, antibody therapeutics for immunological diseases, and multiple antivirals and vaccines related to COVID-19.
Video
 
Deals Of Consequence That Evolved Out Of JPM

In this video segment, three biopharma executives share examples of significant biopharmaceutical industry deals that have evolved out of JPM. This is part of a larger executive virtual roundtable (EVR) on the topic of the 39th Annual JPM Conference being 100% virtual in 2021 and how that is impacting preparations.
Web-Exclusive Content
Contingency Planning For Quality In The Cell And Gene Sector Due To COVID-19
 

Maintaining clinical trials during the COVID-19 pandemic has presented quite a challenge for those companies exploring novel therapies.
Podcasts
023: What’s Hot In Gene Therapy
 

Erin Harris, chief editor of Cell & Gene, reviews some of the hot cell and gene topics for 2020 and what to watch for in 2021. She also discusses the upcoming Cell & Gene Live event and the miniseries she did for the Business of Biotech podcast.
January 2021 Digital Edition
 

Inside you will find more on:

  • Oyster Point Pharma's CEO Interviewed
  • Partnership Strategies From A Halozyme VP
  • Capitol Perspectives
  • Running A Biotech During A Pandemic

View the digital edition.
Contribute To Life Science Leader
Article Submission Guidelines
 

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.